Abstract
The rising prevalence of multi-drug resistant organisms (MDROs), such as Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Enterococci (VRE), and Carbapenem-resistant Enterobacteriaceae (CRE), is an increasing concern in healthcare settings. Leveraging electronic healthcare record data, we developed a data-driven framework to predict MRSA, VRE, and CRE colonization upon intensive care unit admission (ICU), and identify the associated socio-demographic and clinical factors using logistic regression (LR), random forest (RF), and XGBoost algorithms. We performed threshold optimization for converting predicted probabilities into binary predictions and identified the cut-off maximizing the sum of sensitivity and specificity. We achieved the following sensitivity and specificity values with the best performing models: 80% and 66% for VRE with LR, 73% and 77% for CRE with XGBoost, 76% and 59% for MRSA with RF, and 82% and 83% for MDRO (i.e., VRE or CRE or MRSA) with RF. Further, we identified several predictors of MDRO colonization, including long-term care facility exposure, current diagnosis of skin/subcutaneous tissue or infectious/parasitic disease, and recent isolation precaution procedures before ICU admission. Our data-driven modeling framework can be used as a clinical decision support tool for timely predictions, identification of high-risk patients, and selective and timely use of infection control measures in ICUs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study is supported by the U.S. Centers for Disease Control and Prevention (CDC) Modeling Infectious Disease (MInD) Network prime award number 1U01CK000536. The content is solely the responsibility of the authors and does not necessarily represent the official views of the CDC.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
EXEMPTION DECISION: YES The Clemson University Office of Research Compliance reviewed the protocol identified above [IRB2019-255: Multi-level Modeling to Inform Interventions for Control of Multidrug-resistant Organisms within Healthcare Networks] using exempt review procedures and a determination was made on August 23, 2019 that the proposed activities involving human participants qualify as Exempt under category 4 in accordance with federal regulations 45 CFR 46.104(d). The Clemson University IRB is committed to facilitating ethical research and protecting the rights of human subjects. Please contact us if you have any questions and use the IRB number and title when referencing the study in future correspondence. Sincerely, Nalinee D. Patin, CIP IRB Administrator IRB Number: IRB00000481 FWA Number: FWA00004497 OFFICE OF RESEARCH COMPLIANCE Clemson University Clemson Centre 391 College Avenue, Suite 406 Clemson, SC 29631 P 864-656-1525 The Decision: The study IRB2019-255 qualifies exempt from IRB review under category 4 [45 CFR 46.101(b) Categories of Exempt Human Subjects Research]. The information was recorded by the investigators in such a manner that subjects cannot be identified, directly or indirectly through identifiers linked to the subjects. No further action or IRB oversight of the protocol is required except in the following situations: 1. Substantial changes made to the protocol that could potentially change the review level. Researchers who modify the study purpose, study sample, or research methods and instruments in ways not covered by the exempt categories will need to submit an expedited or full board review application. 2. Occurrence of unanticipated problem or adverse event; any unanticipated problems involving risk to subjects, complications, and/or adverse events must be reported to the Office of Research Compliance immediately. 3. Change in Principal Investigator (PI)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data cannot be shared publicly because of private ownership. Data were obtained via electronic healthcare record (EHR) data from the University of Maryland Medical Center (UMMC), an academic teaching hospital located in Baltimore, Maryland.
